RxDoctor Payments DataLook up a doctor →

Daniel Morin, MD

Clinical Cardiac Electrophysiology · San Francisco, CANPI 1306011044

Payments from drug & device makers

$282,271in general payments, 2019–2025

Across 485 payments — averaging $582.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$148K
  • Abbott$57K
  • Boston Scientific$27K
  • Medtronic$23K
  • ZOLL Medical Corporation$14K
  • Altathera Pharmaceuticals LLC$3K
  • plus $11K from 21 others
$2,562in research payments, 2019–2025

Across 2 payments — averaging $1281.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$3K

What the payments were for

  • Consulting fees$52,80220%
  • Speaking & faculty fees$173,87366%
  • Grants$1470%
  • Travel & lodging$18,1517%
  • Food & beverage$20,3358%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$282,271 in reported general payments places this provider in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$87,131
Medicare patients
446
Services billed
1,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban546$581,383
XareltoRivaroxaban463$454,599
MultaqDronedarone Hcl40$46,299
Verapamil SrVerapamil Hcl161$21,690
Dabigatran EtexilateDabigatran Etexilate Mesylate42$13,837
Flecainide Acetate220$10,057
Verapamil ErVerapamil Hcl141$7,708
Metoprolol Succinate448$6,083
Propafenone Hcl ErPropafenone Hcl21$4,959
Amiodarone Hcl199$3,351
Dofetilide30$2,694
Warfarin Sodium111$1,036
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$864
Carvedilol80$675
Metoprolol Tartrate57$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$581,383546 claims
Johnson & JohnsonXarelto$510$454,599463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →